• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Verrica Pharmaceuticals Inc.

    4/22/25 7:18:16 AM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VRCA alert in real time by email
    DEFA14A 1 d900106ddefa14a.htm DEFA14A DEFA14A
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

     

     

    Filed by the Registrant ☒        Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material under § 240.14a-12

    Verrica Pharmaceuticals Inc.

    (Name of Registrant as Specified In Its Charter)

     

    (Name of Person(s) Filing Proxy Statement if Other Than the Registrant)

    Payment of Filing Fee (Check all boxes that apply)

     

    ☒

    No fee required

     

    ☐

    Fee paid previously with preliminary materials

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     
     


    LOGO

    VERRICA PHARMACEUTICALS INC. 44 W. GAY STREET, SUITE 400 WEST CHESTER, PA 19380 Your Vote Counts! VERRICA PHARMACEUTICALS INC. 2025 Annual Meeting Vote by June 4, 2025 11:59 PM ET V71989-P31235 You invested in VERRICA PHARMACEUTICALS INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 5, 2025. Get informed before you vote View the Notice and Proxy Statement and Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 22, 2025. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Point your camera here and vote without entering a control number Vote in Person at the Meeting* June 5, 2025 10:00 AM EDT Company’s Headquarters 44 W. Gay St., Suite 400 West Chester, PA 19380 *Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares.


    LOGO

    Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Voting Items Board Recommends 1. Election of Directors Nominees: 01) Gavin Corcoran 02) Diem Nguyen 03) Sean Stalfort For 2. Approval, on an advisory basis, of the compensation of the Company’s named executive officers as disclosed in the proxy statement. For 3. Ratification of the selection by the Audit Committee of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. For 4. Approval of a series of alternate amendments to the Company’s Amended and Restated Certificate of Incorporation to effect, at the option of the Board of Directors, a reverse stock split of the Company’s common stock at a reverse stock split ratio ranging from 1-for-10 to 1-for-30, inclusive, with the effectiveness of one of such amendments and the abandonment of the other amendments, or the abandonment of all amendments, to be determined by the Board of Directors, in its sole discretion, prior to the date of the 2026 Annual Meeting of Stockholders. For NOTE: Such other business as may properly come before the meeting, including any adjournment or postponement thereof. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V71990-P31235

    Get the next $VRCA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VRCA

    DatePrice TargetRatingAnalyst
    11/6/2024Buy → Neutral
    H.C. Wainwright
    11/5/2024Outperform → Sector Perform
    RBC Capital Mkts
    7/25/2023$10.00Hold → Buy
    Needham
    3/22/2023$10.00Buy
    Jefferies
    2/13/2023$4.00 → $11.00Sector Perform → Outperform
    RBC Capital Mkts
    5/25/2022$16.00 → $4.00Outperform → Sector Perform
    RBC Capital Mkts
    3/10/2022$20.00Buy
    Brookline Capital
    3/3/2022$20.00 → $18.00Buy
    Needham
    More analyst ratings

    $VRCA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer

    WEST CHESTER, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced the appointment of Chris Chapman as its Chief Commercial Officer. "It is my pleasure to welcome Chris Chapman to the Verrica team as our new Chief Commercial Officer," said Jayson Rieger, PhD, MBA, President and Chief Executive Officer. "Chris has an extraordinary track record of successfully commercializing several products in dermatology and other specialties, and has had success in building and leading commercial organizations in dynamic and co

    2/12/26 8:00:00 AM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical

    WEST CHESTER, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced the launch of YCANTH® in Japan by its partner, Torii Pharmaceutical Co. Ltd. ("Torii"), a wholly-owned subsidiary of Shionogi & Co., Ltd., for the treatment of molluscum contagiosum ("molluscum"). "We would like to congratulate our partner, Torii, on the launch of YCANTH in Japan for the treatment of molluscum. Torii's achievement also represents an exciting milestone for Verrica, as we continue to execute on our long-term strategy of developing a

    2/9/26 8:00:00 AM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts

    – Common warts affects approximately 22 million patients in the United States alone, and there are no FDA approved prescription therapies for what is believed to be a multibillion-dollar market opportunity– – Verrica has global rights to YCANTH for all indications in all territories outside of Japan – WEST CHESTER, Pa., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that the first patient was dosed in December 2025 in the global Phase 3 program evaluating YCANTH (VP-102) for the treatment of common warts. "The

    1/7/26 8:00:00 AM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VRCA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for YCANTH issued to VERRICA PHARMACEUTICALS INC

    Submission status for VERRICA PHARMACEUTICALS INC's drug YCANTH (ORIG-1) with active ingredient CANTHARIDIN has changed to 'Approval' on 07/21/2023. Application Category: NDA, Application Number: 212905, Application Classification: Type 5 - New Formulation or New Manufacturer

    7/21/23 4:54:32 PM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VRCA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form 3 filed by new insider Bkb Growth Investments, Llc

    3/A - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)

    2/2/26 9:08:56 AM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Bkb Growth Investments, Llc claimed ownership of 3,348,372 shares (SEC Form 3)

    3 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)

    1/26/26 4:23:59 PM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Interim CFO Kirby John J. was granted 10,000 shares, increasing direct ownership by 112% to 18,962 units (SEC Form 4)

    4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)

    12/30/25 8:00:05 AM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VRCA
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Verrica Pharmaceuticals Inc.

    SCHEDULE 13D/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)

    12/30/25 7:10:47 AM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Verrica Pharmaceuticals Inc.

    8-K - Verrica Pharmaceuticals Inc. (0001660334) (Filer)

    12/30/25 6:05:17 AM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Verrica Pharmaceuticals Inc.

    EFFECT - Verrica Pharmaceuticals Inc. (0001660334) (Filer)

    12/29/25 12:15:05 AM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VRCA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CMO Rosenberg Noah L. bought $10,000 worth of shares (2,357 units at $4.24) (SEC Form 4)

    4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)

    11/25/25 7:00:16 PM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Manning Paul B bought $17,505,157 worth of shares (4,126,142 units at $4.24) (SEC Form 4)

    4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)

    11/25/25 7:00:09 PM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Operating Officer Zawitz David bought $42,425 worth of shares (10,000 units at $4.24), increasing direct ownership by 91% to 21,000 units (SEC Form 4)

    4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)

    11/25/25 7:00:13 PM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VRCA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Verrica Pharmaceuticals downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Verrica Pharmaceuticals from Buy to Neutral

    11/6/24 6:25:52 AM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verrica Pharmaceuticals downgraded by RBC Capital Mkts

    RBC Capital Mkts downgraded Verrica Pharmaceuticals from Outperform to Sector Perform

    11/5/24 6:29:20 AM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verrica Pharmaceuticals upgraded by Needham with a new price target

    Needham upgraded Verrica Pharmaceuticals from Hold to Buy and set a new price target of $10.00

    7/25/23 7:35:00 AM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VRCA
    Financials

    Live finance-specific insights

    View All

    Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025

    WEST CHESTER, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Tuesday, August 12, 2025, to discuss the Company's financial results for the second quarter ending June 30, 2025, and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-800-267-6316 (domestic) or 1-203-518-9783 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10 minutes before the star

    8/6/25 7:00:00 AM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025

    WEST CHESTER, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Tuesday, May 13, 2025, to discuss the Company's financial results for the first quarter ending March 31, 2025, and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-800-343-4136 (domestic) or 1-203-518-9843 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10 minutes before the start of

    5/7/25 8:00:00 AM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025

    WEST CHESTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Tuesday, March 11, 2025, to discuss the Company's financial results for the fourth quarter and full year ending December 31, 2024, and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-800-445-7795 (domestic) or 1-785-424-1699 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10 minut

    3/3/25 7:00:00 AM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VRCA
    Leadership Updates

    Live Leadership Updates

    View All

    Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition

    – Company reported $0 in product shipments in the third quarter of 2024 and recognized negative net product revenue of $1.9 million, including a provision for product returns of $1.7 million– – Company expects existing distributor inventory to support most demand for dispensed applicator units into the first quarter of 2025 – – Company continues to look for ways to manage expenses and expand access to YCANTH® for the treatment of molluscum contagiosum – – Company announces new senior leadership with appointments of Dr. Jayson Rieger as Chief Executive Officer and John Kirby as Interim Chi

    11/4/24 4:05:00 PM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verrica Pharmaceuticals Reports Second Quarter 2021 Financial Results

    WEST CHESTER, Pa., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the second quarter ended June 30, 2021. "This quarter, we continued to ramp up commercial preparations for the potential FDA approval of VP-102, our lead product candidate for the treatment of molluscum contagiosum, including strengthening our senior leadership team and ensuring patient access to VP-102 through productive dialogue with medical providers and payors," said Ted White, Verrica's President and Chief Executive Officer. "With a

    8/10/21 7:30:00 AM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verrica Pharmaceuticals Announces Appointment of Terry Kohler as Chief Financial Officer

    Company strengthens management team in anticipation of the potential commercial launch of VP-102, if approved WEST CHESTER, Pa., July 09, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the appointment of Terry Kohler as Chief Financial Officer. Mr. Kohler is a strategic and operational finance leader with over 20 years of commercial business experience, most recently at a global pharmaceutical company with annual revenues over $2 billion. Mr. Kohler is replacing Brian Davis, who is leaving Verrica to pursue other opportunities. "Te

    7/9/21 7:30:00 AM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VRCA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Verrica Pharmaceuticals Inc.

    SC 13G/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)

    12/9/24 6:22:49 PM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Verrica Pharmaceuticals Inc.

    SC 13D/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)

    11/26/24 4:15:26 PM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Verrica Pharmaceuticals Inc.

    SC 13G/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)

    11/14/24 9:32:46 AM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care